U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Advisory Committees
  3. Committees and Meeting Materials
  4. Human Drug Advisory Committees
  5. Obstetrics, Reproductive and Urologic Drugs Advisory Committee (formerly Bone, Reproductive and Urologic Drugs Advisory Committee)
  1. Human Drug Advisory Committees

Obstetrics, Reproductive and Urologic Drugs Advisory Committee (formerly Bone, Reproductive and Urologic Drugs Advisory Committee)

Meeting materials from 2018 and older are archived.
To view them, please see the FDA Archive

Purpose

The Committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drug products for use in the practice of obstetrics, gynecology, urology and related specialties, and makes appropriate recommendations to the Commissioner of Food and Drugs.

Committee Membership

The Committee shall consist of a core of 11 voting members including the Chair.  Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of obstetrics, gynecology, urology, pediatrics, epidemiology, or statistics and related specialties. Members will be invited to serve for overlapping terms of up to four years.  Non-Federal members of this committee will serve as Special Government Employees, representatives or Ex-Officio members.  Federal members will serve as Regular Government Employees or Ex-Officios.  The core of voting members may include one technically qualified member, selected by the Commissioner or designee, who is identified with consumer interests and is recommended by either a consortium of consumer-oriented organizations or other interested persons.  In addition to the voting members, the Committee may include one non-voting representative member who is identified with industry interests.  There may also be an alternate industry representative.

Contact Information

Joyce Frimpong, PharmD
Designated Federal Officer (DFO)
Division of Advisory Committee and Consultant Management
Office of Executive Programs
E-mail: ORUDAC@fda.hhs.gov

FDA Advisory Committee Information Line
1-800-741-8138
(301) 443-0572 (local number)
Please call the Information Line for up-to-date information on meetings.

Resources For You

Contact Information

FDA Advisory Committee Information Line
1-800-741-8138
(301-443-0572 in the Washington DC area)

Please call the Information Line for up-to-date information on this meeting.

Back to Top